25I-NBOMe molecular structure — one example within this group.
PubChem / National Library of Medicine · Structure images reusable under PubChem citation guidelinesAbout NBOMe compounds
NBOMe describes a family of synthetic psychedelic compounds, including 25I-NBOMe, 25B-NBOMe and 25C-NBOMe. It is not a synonym for LSD.
Also searched as: N-Bomb
Buy NBOMe compounds: pricing & legal access
NBOMe compounds online: availability & product information
The listed 25I-, 25B- and 25C-NBOMe compounds are Schedule I substances. DrugRX provides no consumer price, seller referral or claim that a research label creates lawful access.
Pricing status: No live price feed or verified quote. DrugRX does not sell or dispense products.
Sources: DEA — Controlled substances alphabetical list (October 2026)
NBOMe compounds information
Why compound identity matters
Different NBOMe names identify different compounds. A blotter format or a product sold as “acid” cannot establish which chemical is present.
Sources: DEA — 25I-, 25C- and 25B-NBOMe
Severe toxicity risks
DEA reports serious adverse effects associated with these compounds, including agitation, seizures and cardiovascular toxicity. A severe reaction requires emergency medical care.
Sources: DEA — 25I-, 25C- and 25B-NBOMe
Dosage and interactions
This family does not have an established consumer self-treatment dose. Do not transfer assumptions about LSD or one NBOMe compound to another.
Sources: DEA — 25I-, 25C- and 25B-NBOMe
What the NBOMe names mean
The 25I, 25B and 25C names identify different compounds, not different spellings of the same ingredient. They are related to particular phenethylamine structures and have been investigated as serotonin-receptor ligands.
Sources: DEA — 25I-, 25C- and 25B-NBOMe
NBOMe is not LSD
These compounds have been marketed as other hallucinogens. Blotter paper is a delivery format, not a chemical identifier; artwork or a street name cannot establish which substance is present.
Sources: DEA — 25I-, 25C- and 25B-NBOMe
Toxicity and medical assessment
Severe agitation, seizures, overheating and cardiovascular toxicity have been associated with NBOMe compounds. A history of a product sold as acid should therefore be reported as a product description rather than a confirmed LSD exposure.
Sources: DEA — 25I-, 25C- and 25B-NBOMe
Family-level versus compound-level evidence
An observation about 25I-NBOMe should identify that compound and the tested material. It does not automatically define every member of a chemical family. The directory retains the family heading while spelling out the important named members.
Sources: DEA — 25I-, 25C- and 25B-NBOMe
Sources and editorial notes
Prepared by DrugRX using the references linked below. Sources were consulted on 2026-10-31. This page has not been independently reviewed by a clinician. Research findings, medication approval and legal permission are separate questions.
Legal information is a dated U.S. reference. Product rules and local laws may change. Where the evidence does not establish a dose, interaction profile or price, the page states that limitation.